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Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have a protective cardiorenal 27 
effect in type 2 diabetes. This systematic review examines the effects of SGLT2is on 28 
clinical biomarkers of inflammation and oxidative stress. 29 
Methods 30 
A search of Medline, Embase, Web of Science, and The Cochrane Library was 31 
performed examining changes in selected clinical biomarkers for inflammation: c-32 
reactive protein (CRP), adiponectin, interleukin-6 (IL6), tumour necrosis factor-alpha 33 
(TNF-α), and oxidative stress: 8-iso-prostaglandin F2α (8-iso-PGF2α) and 8-hydroxy-34 
2'-deoxyguanosine (8-OHdG). Quality of evidence was evaluated using the 35 
GRADEpro tool and risk of bias was assessed using the Cochrane RoB 2 and 36 
ROBINS-I tools. 37 
Results 38 
A total of 23 (15 randomised, 8 observational) heterogeneously-designed clinical 39 
studies were identified (1,654 patients, 24 weeks median follow-up). Consistent 40 
reductions were observed for CRP (10/12 studies), IL6 (5/5 studies), TNFα (3/4 41 
studies), 8-iso-PGF2α (3/4 studies) and 8-OHdG (2/2 studies), and a consistent 42 
increase in adiponectin (6/8 studies). Change in serum CRP following SGLT2is 43 
appear to be independent of change in HbA1c and other study design and clinically 44 




There is heterogeneous, yet consistent data supporting the beneficial effects of 47 
SLGT2is on inflammatory and oxidative stress. Change in serum CRP appears to be 48 
independent of change in HbA1c.  49 
 50 
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Type 2 diabetes mellitus (T2DM) is associated with considerable morbidity and 65 
mortality, with cardiovascular disease (CVD) accounting for over 50% of deaths (1) 66 
and diabetes-related kidney disease (DKD) accounting for up to 50% of all cases of 67 
end-stage renal failure (2). Furthermore, the risk of cardiovascular (CV) death is 68 
increased in the setting of T2DM with end-stage renal failure (3). CV mortality is due 69 
to a combination of atherosclerotic disease and heart failure (HF). Compared to 70 
patients without diabetes, those with T2DM are twice as likely to develop coronary 71 
artery disease (4) and 2-6 times more likely to have HF (5).  72 
 73 
Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have an established, yet 74 
unexplained cardiorenal protective effect (6-9). These agents act on sodium-glucose 75 
cotransporter-2 channels in the proximal convoluted tubule to promote glycosuria, 76 
and thereby improve glycaemic control and reduce glycated haemoglobin (HbA1c) 77 
(10). The major clinical trials investigating the effects of SGLT2is in relation to CV 78 
and renal outcomes include the Empagliflozin Cardiovascular Outcome Event Trial in 79 
Type 2 Diabetes Mellitus Patients (EMPA-REG); Canagliflozin Cardiovascular 80 
Assessment Study (CANVAS); the Multicenter Trial to Evaluate the Effect of 81 
Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI 58) and 82 
the Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy 83 
(CREDENCE) trial (6-8, 11). A recent meta-analysis by Toyama et al, confirmed the 84 
benefits of SGLT2is (12). SGLT2is reduce the risk of hospitalisation or death due to 85 
HF by approximately 39%; decline in renal function by 29%; and 3-point major 86 
adverse CV events (MACE) (defined as CV death, non-fatal myocardial infarction or 87 
stroke) by 19%. The greatest benefits appear to be in reducing HF with a collective 88 
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reduction in relative risk of 39%. The CV benefits from SGLT2is are most apparent in 89 
patients with more advanced diabetes and established CV disease. This has been 90 
summarised in a meta-analysis by Zelniker et al (13). Indeed, patients without 91 
established CVD (but with CV risk factors) do not see a benefit in the 3-point MACE 92 
as opposed to patients with established CVD, where a 14% relative risk reduction is 93 
observed. SGLT2is also reduce the risk of renal composite outcomes by 33%, 44% 94 
and 56% in patients with an estimated glomerular filtration rate (eGFR) ≥90, 60-90 95 
and <60 mL/min/m3, respectively (13). This has now been taken into account in 96 
current guidelines, which recommended the use of SGLT2is in T2DM with 97 
established CVD, HF or chronic kidney disease (14).  98 
 99 
SGLT2is appear to have pleiotropic effects in patients with T2DM that are 100 
unexplained by improved glycaemic control alone (15). T2DM is a condition 101 
associated with increased inflammation and oxidative stress (16, 17). Furthermore, 102 
inflammation is recognised in the pathogenesis of atherosclerosis (18) and DKD 103 
(19). Targeting inflammatory pathways have been shown to reduce the rate of 104 
recurrent cardiovascular events (20). Emerging evidence from basic scientific studies 105 
supports the view that SGLT2is may influence inflammation and oxidative stress (21-106 
24) and that this may contribute to the improved outcomes associated with these 107 
agents. This systematic review aims to provide a comprehensive summary of the 108 
available clinical evidence examining the effects of SGLT2is on biomarkers of 109 
inflammation and oxidative stress. 110 
 111 
Methods 112 
Search Strategy 113 
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Medline, Embase, Web of Science, and the Cochrane Library were searched up to 114 
December 2019 using the following search terms:- (gliflozin* OR SGLT$2 inhibitor* 115 
OR SGLT2 inhibitor* OR sodium glucose cotransporter 2 inhibitor*) AND 116 
(inflammation/oxidative stress OR biomarkers). See PROSPERO 117 
(CRD42020180276) and supplementary table 5a and 5b for full search strategy. 118 
Where possible Mesh terms were used. This search strategy is illustrated in figure 119 
1a. Two reviewers screened titles, and abstracts if necessary, to select clinical 120 
studies examining the effects of SGLT2is on inflammatory or oxidative stress 121 
biomarkers.  122 
 123 
Published articles without original data including reviews, expert opinion, 124 
commentary and responses were excluded, along with research examining non-125 
human or in vitro experiments. We included randomised controlled trials with a 126 
parallel and crossover design, along with observational studies. Both prospective 127 
and retrospective studies were included. All comparison designs were acceptable 128 
including studies comparing SGLT2i treated participants to placebo or standard 129 
diabetes therapies. Studies relating to canagliflozin, empagliflozin, dapagliflozin and 130 
luseogliflozin were included. There were no constraints applied to the use of 131 
concomitant antidiabetes medication, publication status, nor language. The study 132 
was conducted in-line with the Preferred Reporting Items for Systematic Reviews 133 
and Meta-Analyses (PRISMA) checklist. The selection process for publications is 134 
illustrated in figure 1b.  135 
 136 
Selected biomarkers 137 
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A priori, we selected biomarkers widely accepted and reported in the scientific 138 
literature to be direct and effective indicators of inflammation and oxidative stress, 139 
these included inflammatory biomarkers: c-reactive protein (CRP), adiponectin, 140 
interleukin-6 (IL6), tumour necrosis factor-alpha (TNF-α), and oxidative stress 141 
biomarkers: 8-iso-prostaglandin F2α (8-iso-PGF2α) and 8-hydroxy-2'-142 
deoxyguanosine (8-OHdG). Those with unproven validity or unclear significance in 143 
inflammation and oxidative stress were excluded.  144 
 145 
Data extraction and quality assessment 146 
Data was extracted to pre-formatted tables including study design, participant 147 
characteristics (table 1), and outcome measures. These data were used to produce 148 
a description of the serum inflammatory biomarker changes (table 2a) and changes 149 
in biomarkers of oxidative stress (table 2b). Original raw data extracted from studies 150 
can be found in supplementary table 1a and 1b. The strength of evidence was 151 
appraised using the Grading of Recommendations Assessment, Development and 152 
Evaluation (GRADEpro) tool (25) (supplementary table 2). Study quality was 153 
assessed using the Cochrane Risk-of-Bias Tool for Randomised trials (RoB 2) tool 154 
(26) and the Risk of bias in non-randomised studies of interventions (ROBINS-I) tool 155 
(27) (supplementary table 3a and 3b).  156 
 157 
Associations with change in c-reactive protein (CRP) 158 
We chose a priori to examine the relationship between change in inflammatory 159 
markers and mean blood glucose (HbA1c), study design factors (participant co-160 
morbidity, pharmacological intensity, study follow-up period and SGLT2i 161 
concentration) and clinically relevant variables (eGFR, body mass index (BMI) and 162 
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homeostatic model assessment of insulin resistance (HOMA-IR)). As CRP was the 163 
most widely reported inflammatory biomarker, absolute change in CRP from 164 
observational and randomised studies and placebo-subtracted change in CRP from 165 
randomised controlled trials were correlated with the aforementioned variables, 166 
where available. In order to stratify participant co-morbidity, a validated multiscore 167 
co-morbidity score based on mortality by Corrao et al was used to assign a score to 168 
each study (supplementary table 4) which was then correlated with change in CRP 169 
(28). In order to correlate pharmacological intensity with change in CRP, studies 170 
including participants on no antidiabetic medications received a 0, a single agent 171 
received a 1 and more than one agent received a 2 (supplementary table 4). 172 
 173 
Statistics  174 
Using IBM SPSS (version 25) parametric tests, and where relevant non-parametric 175 
tests, were used to assess for linear correlations. Weighted means were weighted by 176 
study number (n). Where available, results from comparison with placebo/ standard 177 
care were preferentially included over comparison with baseline. Funnel plots used 178 
to visually assess for publication bias and tests for heterogeneity including the I2 179 
statistic were performed using Review Manager (RevMan) 5.3, Copenhagen: The 180 
Nordic Cochrane centre 2014. Control-subtracted change takes account of both the 181 
control and active group within a single value. This was calculated by subtracting the 182 
control group value from the SGLT2i group value for both baseline and follow-up, 183 
before subtracted the resultant baseline value from the follow-up value. Where 184 
possible standard deviation (SD) were estimated from available information using the 185 
validated calculation outlined in the Cochrane Handbook (29). A p value of <0.05 186 





From the 23 clinical studies identified, there were 1654 participants (1361 190 
inflammation, 201 oxidative stress, 92 both) treated with SGLT2is with data relating 191 
to the relevant biomarkers. The included studies were heterogeneous in design but 192 
predominantly randomised controlled trials (15 randomised clinical trials, 8 193 
observational studies). All of the data analysed were collected prospectively. Three 194 
publications involved post-hoc analyses of previous prospective trials:- two from the 195 
CANagliflozin Treatment And Trial Analysis versus SUlphonylurea (CANTATA-SU) 196 
trial (30, 31) and 1 from Petrykiv et al (32).  197 
 198 
Participant characteristics can be found in table 1. All participants had T2DM, with 199 
most studies documenting a maximum HbA1c of approximately 10%. Five studies 200 
included participants who were overweight (BMI >25kg/m2) or had the metabolic 201 
syndrome (33-37); three studies included participants with non-alcoholic liver 202 
disease (NAFLD) or non-alcoholic steatohepatitis (NASH) (36, 38, 39); one study 203 
included participants with HF (40); and one study recruited participants with coronary 204 
artery disease (41). The median number of participants recruited in the studies was 205 
35, with a range from 11-296. All participants were aged 18 years or above, and 206 
57.9% of participants were male. Studies were mainly composed of Japanese 207 
participants (33, 34, 37-45); but there were also participants from Germany (46), the 208 
Netherlands (32), Sweden (30), the United States of America (47), Spain (48), Italy 209 
(49), China (50), and worldwide (31, 51, 52). The daily doses of the SGLT2i was 210 
2.5mg for luseogliflozin, 100mg-300mg for canagliflozin (mostly 100mg), 10mg-25mg 211 
for empagliflozin, and 5mg-10mg for dapagliflozin. The median duration of follow-up 212 
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was 24 weeks (range: 2 days to 104 weeks). All 6 biomarkers for inflammation and 213 
oxidative stress (CRP, adiponectin, IL6, TNF-α, 8-iso-PGF2α and 8-OHdG) showed 214 
significant heterogeneity (I2 >75%, p < 0.10) (analysis not included).  215 
 216 
Within the studies, five studies did not report on the loss of participants to follow-up 217 
(33-35, 46, 50). In addition, ≥5% loss to follow-up was observed in eight studies (30, 218 
31, 36, 38, 42, 44, 48, 51); and loss to follow-up was unequal across treatment arms 219 
in four studies (30, 31, 42, 51). One study utilised a modified intention-to-treat 220 
analysis (32). Of our selected inflammatory biomarkers (CRP, adiponectin, IL6 and 221 
TNF-α) and the one most reported oxidative stress biomarker (8-iso-PGF2α), the 222 
strength of evidence as identified by the GRADE system is summarised in 223 
supplementary table 2. The quality of evidence from randomised studies was 224 
considered high for 8-iso-PGF2α, moderate for CRP, adiponectin, IL6 and TNF-α, 225 
and low for all biomarkers from observational studies. The RoB 2 tool was used to 226 
assess 12 randomised studies for risk of bias (supplementary table 3a). Six studies 227 
were thought to be of ‘low’ risk of bias (32, 36, 39, 44, 45, 52); seven studies as 228 
warranting ‘some concern’ (30, 31, 33, 37, 41, 46, 50) and two studies as being at 229 
‘high’ risk of bias (40, 51). The ROBINS-I tool was used to assess eight 230 
observational studies for risk of bias (supplementary table 3b). Six studies were 231 
considered ‘moderate’ risk of bias (34, 35, 38, 43, 47, 49), and two studies were 232 
considered ‘serious’ risk of bias (42, 48). Of the 23 studies, three did not comment 233 
on gender identity and nine studies included males with a prevalence ≥70% (33, 36, 234 
37, 40, 41, 43, 45, 47, 48).  235 
 236 
Inflammatory biomarkers 237 
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Our four selected inflammatory biomarkers were:- CRP in 12 studies; adiponectin in 238 
8 studies; IL6 in 5 studies; and TNF-α in 4 studies. Results are summarised in table 239 
2a and 2b. 240 
 241 
C-reactive protein (CRP) 242 
Of the 12 studies (7 randomised, 5 observational, n=732) which evaluated CRP, 243 
83% (10/12) demonstrated a reduction in hs-CRP or CRP compared to pre-treatment 244 
levels or placebo (30, 33, 35-38, 40, 42, 48, 52). All studies show results of change 245 
in CRP compared with baseline, and 6/12 studies also reported comparison with 246 
standard care (2/12) (30, 42) or placebo (4/12) (33, 36, 46, 52). The weighted mean 247 
reduction for absolute change in CRP was -0.228 (standard deviation 0.197) and the 248 
weighted mean percentage change was 27.6% (standard deviation 30.4%). These 249 
reductions showed marked variation which might be explained by the heterogeneity 250 
in the designs of the studies. 42% (5/12) reported statistically significant reductions 251 
in CRP associated with SGLT2is (33, 35, 38, 40, 48). Of these 4 studies, the study 252 
described by Hattori, was the largest randomised study and demonstrated a marked 253 
significant decrease in hs-CRP associated with empagliflozin therapy at a dose of 254 
10mg/day (-74.4% compared to placebo and -55.6% compared to pre-treatment 255 
levels at 12 months) (33). In the CANOSSA trial (prospective, open-label, add-on 256 
trial of canagliflozin for diabetes mellitus and stable chronic HF) (40) during the 12 257 
months follow-up there was a significant reduction in hs-CRP (-46.2%) associated 258 
with canagliflozin therapy at a dose of 100mg/day. However, CRP (non hs-CRP) was 259 
numerically reduced, though not significantly. The smaller, observational study by 260 
Tobita et al, examined 6 months of therapy with dapagliflozin (5mg/day), and 261 
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observed a significant disease (-53.8%) in CRP compared to pre-treatment levels 262 
(38). Similarly, a randomised study by Okamoto et al, reported a -33.3% reduction in 263 
CRP at 12 weeks associated with 5mg/day of dapagliflozin (35). Iannantuoni et al, in 264 
a small (n=17), observational study which collected hs-CRP samples from older (40-265 
70 years) participants with longstanding T2DM (>10 years) after 24 weeks of 266 
10mg/day empagliflozin (48). Compared with baseline, hs-CRP was significantly 267 
reduced. The absence of a significant decrease in CRP in the other studies might be 268 
explained by a combination of:- (i) the recruitment of participants with fewer co-269 
morbidities and hence a lower co-morbidity score (30, 42, 46, 52); (ii) the exclusion 270 
of participants with CRP levels above a prespecified level (e.g. >10mg/L (24); 271 
>5mg/L) (46); (iii) small participant study numbers which were insufficiently powered 272 
(n≤20) (37, 42, 43); (iv) inadequate length of follow-up (≤3 months) (36, 42, 43, 46); 273 
(v) observational study design and thus risk of bias (42, 43); and (vi) authors did not 274 
comment on statistical significance (30). 275 
 276 
Associations with change in c-reactive protein (CRP) 277 
Absolute change in CRP from baseline to follow-up was not significantly associated 278 
with:- (i) absolute change in HbA1c (n=8, r=-0.122, p=0.773, figure 2), (ii) participant 279 
co-morbidity (n=10, r=0.288, p=0.419), (iii) pharmacological intensity (n=10, r=0.038, 280 
p=0.918), (iv) study follow-up period (n=10, r=0.263, p=0.463), (v) SGLT2i 281 
concentration (n=10, r=0.116, p=0.749), (vi) absolute change in eGFR (n=6, r=-282 
0.545, p=0.264), (vii) absolute change in BMI (n=4, r=-0.077, p=0.923) and (viii) 283 
absolute change in HOMA-IR. Looking specifically at randomised controlled trials, 284 
placebo-subtracted change in CRP was not significantly associated with:- (i) 285 
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placebo-subtracted change in HbA1c (n=4, r=0.400, p=0.600), (ii) study length (n=4, 286 
-0.641, p=0.359), (iii) SGLT2i concentration (n=4, r=0.177, p=0.823), (iv)  participant 287 
co-morbidity (n=5, r=0.129, p=0.836) and (v) pharmacological intensity (n=5, 288 
r=0.198, p=0.750). 289 
 290 
Adiponectin 291 
With respect to adiponectin, eight studies (5 randomised, 3 observational, n=553) 292 
investigated changes in adiponectin following SGLT2is. All studies report data on 293 
change in adiponectin relative to baseline, and 4/8 report comparison with either 294 
standard care (2/8) (30, 39) or placebo (2/8) (36, 51). Of these eight studies, 75% 295 
(6/8) described an increase in adiponectin, (30, 34, 35, 38, 39, 51) and of which four 296 
studies (4/8) described were significant (34, 35, 38, 39) and two studies did not 297 
comment on the statistical significance. The largest randomised study (n=282) did 298 
not comment on significance but showed an increase in adiponectin (51). Bailey et 299 
al, described an increase in adiponectin associated with dapagliflozin with 1, 2.5 and 300 
5mg/day doses at 3 months compared to placebo and from pre-treatment levels in 301 
treatment naïve participants with T2DM. Similarly, Aso et al, report a significant 302 
increase (+50.0%) in adiponectin following 3 months of therapy with dapagliflozin 303 
(5mg/day) compared to pre-treatment levels and a control-subtracted increase of 304 
+56.0% (39). Garvey et al, described a non-significant increase in adiponectin 305 
(+17.1%) following 52 weeks of canagliflozin 300mg/day compared with glimepiride 306 
6mg or 8mg/day in a sample of participants with fewer co-morbidities (30). Other 307 
studies, which showed a significant increase in adiponectin, were generally smaller 308 
and showed increases of +22.9% (dapagliflozin 5mg/day, n=11, duration 6 months) 309 
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(34); +9.4% (canagliflozin 100mg/day, n=15, duration 7 days) (34); and +33.3% 310 
(dapagliflozin 5mg/day, n=27, duration of 3 months) (35). A further three studies 311 
investigating dapagliflozin and luseogliflozin described small, non-significant 312 
decreases in adiponectin (32, 36, 37).  313 
 314 
Interleukin 6 (IL6) 315 
There were four published datasets (3 randomised, 1 observational, n=347, from 5 316 
studies) which examined changes in IL6 following use of SGLT2i (30-32, 37, 47). 4/5 317 
studies reported data on IL6 compared with baseline, (30, 32, 37, 47) and 3/5 318 
reported data compared with standard care (2/5) (30, 31) or placebo (1/5) (32). Both 319 
Heerspink and Garvey et al, performed a post-hoc analysis from the CANTATA-SU 320 
trial (30, 31). Of the studies that investigated changes in IL6 compared to pre-321 
treatment levels, placebo or standard care, all showed a decrease in plasma IL6, 322 
with 80% (4/5) of these describing significant decreases (31, 32, 47, 48). Heerspink 323 
et al, measured plasma IL6 in 296 samples from the CANTATA-SU trial (31). They 324 
observed a significant and substantial decrease in IL6 associated with 100mg/day 325 
and 300mg/day of canagliflozin following 104 weeks of therapy (-26.3% and -26.6%, 326 
respectively). Tan and Tan, in a study comparing the efficacy of empagliflozin with 327 
canagliflozin observed that following 6 months of treatment, empagliflozin 10mg/day 328 
was superior and was associated with a significant decrease in IL6 by -52.0% (47). 329 
The randomised study by Dekkers et al, observed a significant decrease in IL6 330 
compared with baseline following dapagliflozin therapy at a dose of 10mg/day (32). 331 
Bouchi et al, reported a non-significant decrease in IL6 (-33.0%) with luseogliflozin 332 
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(2.5mg/day) compared with baseline, but was not powered for the purpose of 333 
examining change in IL6, including only 19 participants (37).  334 
 335 
Tumour necrosis factor alpha (TNF-α) 336 
Four studies (2 randomised, 2 observational, n=187) have investigated changes in 337 
TNF-α (30, 34, 41, 47), all of which reported changes in TNF-α compared with 338 
baseline and 2/4 (30, 41) report changes compared with standard care. 75% (3/4) 339 
described a decrease (34, 41, 47) with 50% (2/4) showing a statistically significant 340 
decrease with SGLT2is (41, 47). Both studies were of a moderate size with a follow-341 
up period of 6 months. Tan and Tan (n=32), observed a significant decrease in TNF-342 
α of -37.4% (47) following treatment with 10mg/day of empagliflozin in a sample of 343 
males. Sato et al (n=40), observed a decrease of -22.1% associated with 344 
dapagliflozin (dose unspecified) in a sample of T2DM participants with coronary 345 
artery disease (41). The remaining two studies did not show significant reductions, 346 
but of note, these recruited participants with fewer co-morbidities, (30) and were 347 
insufficiently powered with a short follow-up (34).  348 
 349 
Oxidative Stress 350 
Our two selected oxidative stress biomarkers were:- 8-iso-PGF2α in 4 studies and 8-351 
OHdG in 2 studies. Results are summarised in table 2a and 2b. 352 
 353 
8-iso-prostaglandin F2α (8-iso-PGF2α) 354 
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Four studies (3 randomised, 1 observational, n=146) investigated 8-iso-PGF2α 355 
levels with three reporting urinary levels (36, 45, 49) and one reporting serum levels 356 
(50). 75% of these studies report significant decreases in 8-iso-PGF2α levels 357 
following use of SGLT2is. The randomised trial by Nishimura et al, (n=60) observed 358 
a significant decrease in fasting urinary 8-iso-PGF2α at 28 days following treatment 359 
with empagliflozin 10mg/day (-45.5%) and empagliflozin 25mg/day (-50.5%) relative 360 
to placebo (45). Similarly the observational study by Solini et al, (n=16) reported a 361 
significant  decrease (-30.3%) in urinary 8-iso-PGF2α levels 2 days after a single 362 
10mg dose of dapagliflozin (49). Similar serum measurements have been observed 363 
in the randomised trial (n=28) by Zhou et al, in which 24 weeks of dapagliflozin 364 
(between 5mg-10mg) was associated with a significant decrease in serum 8-iso-365 
PGF2α levels compared with placebo (50).  Eriksson et al, studied T2DM patients 366 
with concomitant NAFLD and reported non-significant increases in  urinary 8-iso-367 
PGF2α/creatinine ratio (+12.3%) and urinary 2,3-dinor-8-iso-PGF2α/creatinine 368 
(+18.2%) following 12 weeks of 10mg/day  dapaglifozin compared with placebo (36). 369 
At 24 hours post-drug administration, they also observed a significant decrease in 370 
urinary 8-iso-PGF2α following empagliflozin 25mg/day (-43.1%) and a non-significant 371 
decrease following empagliflozin 10mg/day (-24.7%).  372 
 373 
8-hydroxy-2'-deoxyguanosine (8-OHdG) 374 
Two studies (1 randomised, 1 observational, n=95) report urinary 8-OHdG levels (34, 375 
44) and both report a significant decrease following SGLT2is. Shigiyama et al, 376 
published the DEFENCE (Dapagliflozin EFfectiveness on vascular ENdothelial 377 
function and glycemic Control in patients with Early-stage type 2 diabetes mellitus) 378 
study (n=80), which examined participants receiving 750mg/day of metformin and 379 
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who were randomised to dapagliflozin 5mg/day dapagliflozin (SGLT2i) or metformin 380 
1500mg/day (control) (44). At 16 week follow-up, they observed a significant 381 
decrease (-34.8%) in the urinary 8-OHdG/creatinine ratio in the dapagliflozin group 382 
compared to control. Of note, this change was non-significant compared to baseline 383 
(-13.0%). The observational study in stable, insulin-treated patients with T2DM by 384 
Matsumura et al (n=15), reported a significant decrease (-5.3%) in urinary 8-385 
OHdG/creatinine ratio relative to pre-treatment levels following 3 days of 386 
canagliflozin 100mg/day (34). 387 
 388 
Discussion 389 
This systematic review of 23 studies with 1654 patients summarises the current 390 
available literature, which examine the effects of SGLT2is on inflammatory and 391 
oxidative stress biomarkers. We have observed that SGLT2is were associated with 392 
significant decreases in CRP, IL6, TNF-α, 8-iso-PGF2α, and 8-OhdG, along with 393 
significant increases in adiponectin. The association of T2DM with inflammation and 394 
oxidative stress is well established (53-55). Indeed, many diabetes medications have 395 
anti-inflammatory and anti-oxidant effects (56, 57). Our data support the hypothesis 396 
that SGLT2is decrease inflammation and oxidative stress in T2DM. 397 
 398 
Beyond the markers examined in this review, other less investigated biomarkers 399 
such as leptin also show SGLT2i-associated decreases (47). Interestingly 400 
inflammatory markers specific to atherosclerosis, such as RLP-C, are limited but 401 
demonstrate significant reductions (33, 40). By clarifying the effect of SGLT2is on 402 
inflammatory and oxidative stress pathways this could contribute to establishing new 403 




Association between clinical and laboratory-based evidence  406 
There is consistent evidence from animal models that SGLT2is ameliorate the 407 
inflammatory and oxidative stress profile observed with T2DM. Tahara et al, used a 408 
murine model of T2DM to demonstrate significant reductions in plasma CRP, TNF-α 409 
and IL6 following 4 weeks of therapy with 3mg/kg/day of ipragliflozin (58). In addition, 410 
other published studies report reductions in IL6 and TNF-α with SGLT2is. Studies 411 
using cell culture cytotoxic assays in human endothelial cells (59), human and mice 412 
immune cells (60) have observed that canagliflozin is associated with a reduction in 413 
IL6 and TNF-α. Of interest, no reduction has been observed in these cytokines in 414 
endothelial cells treated empagliflozin or dapagliflozin (59). Treatment with 415 
empagliflozin has been associated with a decreased expression of IL6 in a murine 416 
model of DKD (61), along with TNF-α in high-fat-diet induced obese mice (62). Gene 417 
expression microarrays of mouse adipose tissue have shown that an obese murine 418 
model of T2DM is associated with down-regulation of adipocytokines including 419 
adiponectin, and this is re-upregulated by dapagliflozin (63). In the mouse model of 420 
atherosclerosis (apolipoprotein E knockout), canagliflozin was associated with 421 
reduced expression of inflammatory molecules including monocyte chemoattractant 422 
protein-1 (MCP-1) and VCAM-1 (64). The authors suggest that this was associated 423 
with histological changes demonstrating a slowing of atherosclerosis. Within these 424 
studies, it is difficult to compare study design, follow-up time and dose as these 425 
experiments are based in animal models. 426 
 427 
Very few animal model studies have examined markers of iso-8-PGF2α. Salim et al, 428 
observed reductions in 8-OHdG in a murine model of T2DM following treatment with 429 
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3mg/kg/day of ipragliflozin (65). In addition Osorio el al, described an increase in 430 
catalase and a decrease in glutathione peroxidase in the diabetic rat kidney cortex 431 
and medulla following treatment with phlorizin (66). Using streptozotocin toxicity as a 432 
model of diabetes, Oelze et al, reported that NADPH oxidase activity in rat heart 433 
membranes was increased following streptozotocin treatment, but dose-dependently 434 
inhibited by SGLT2is (67). Such changes are consistent with the findings of our 435 
systematic review.  436 
 437 
How do SGLT2 inhibitors exert such effects? 438 
The mechanism by which SGLT2is decrease inflammation in T2DM remains unclear. 439 
There appears to be an interplay between oxidative stress and inflammation that is 440 
independent of reduced inflammation as a result of improved glycaemic control (68). 441 
One proposed hypothesis suggests that SGLT2is suppress the up-regulation of the 442 
NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome (69). 443 
Another hypothesis relates to a possible role that SGLT2is inhibit intracellular 444 
glucose metabolism leading to increased autophagy and a resultant dampening of 445 
the inflammatory response (60). 446 
 447 
Limitations of study 448 
The current evidence base consists of a heterogeneous group of studies, 449 
predominantly at ‘moderate’ risk of bias, and often underpowered to reliably detect 450 
changes in serum inflammatory and oxidative stress biomarkers. Due to study 451 
design heterogeneity and unavailability of data, it was not possible to perform a 452 
meta-analysis. A focus of further studies should be to increase the power of any 453 
results in order to enable a more accurate interpretation of findings. 39% of included 454 
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studies included ≥70% male participants, although this only amounted to 57.9% of 455 
total participants being male in this study. Moreover, the prevalence of T2DM is 456 
higher in males (70) and therefore the generalisability of our results is unlikely to be 457 
compromised. Another limitation of our study was the selection of adequate 458 
biomarkers, for instance, uric acid was excluded from our study as it has both anti-459 
oxidant and pro-oxidant properties depending on its location, in plasma or cytoplasm 460 
(71). There is also emerging evidence that certain markers believed to be gold-461 
standard are imperfect markers of inflammation or oxidative stress (72). Future 462 
clinical studies must attempt to ensure the validity of any biomarkers investigated.  463 
 464 
Conclusion 465 
Despite the heterogeneity of the available published studies and based on 466 
predominantly ‘moderate’ quality data, the findings of this review supports evidence 467 
that SGLT2is reduce inflammation and oxidative stress associated with T2DM at 468 
short- and long-term follow-up. This may partly explain the CV and renal benefits of 469 
SGLT2is. The beneficial effect of SGLT2is on measurements of serum CRP appear 470 
to be independent of many study design and clinically relevant variables, including 471 
HbA1c. 472 
 473 
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 Figure 1a: Search Strategies 737 
No Searched Terms - Inflammation Searched Terms - Oxidative Stress 
1 gliflozin* gliflozin* 
2 Sglt$2 inhibitor* Sglt$2 inhibitor* 
3 sglt2 inhibitor* sglt2 inhibitor* 
4 sodium glucose cotransporter 2 inhibitor* sodium glucose cotransporter 2 inhibitor* 
5 OR/1-4 OR/1-4 
6 Inflammation  Oxidative Stress  
7 Biomarker* Biomarker* 
8 6 OR 7 6 OR 7 
9 5 AND 8 5 AND 8 
 738 





(Figure 1a) Search strategy used to search Medline, Embase, Web of Science, and the 742 
Cochrane Library. (Figure 2b) Resulting articles found and reasons for exclusion. 743 
Keywords: (*) = ending variant, ($) = truncation. 744 
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Table 1: Study and population characteristics  
 
Study Type of Study Number 
randomised  
(n) 




Loss to follow-up 
(%) 
Inclusion criteria 




17 60.8  
(±10.2) 
73% 11.8% T2DM 
 







59% - T2DM 
Heerspink et al, 2019 































78% 0% T2DM, HF 











31 62.0  
(±8.1) 


















T2DM, NAFLD, BMI (25–40 kg/m2) 
Hattori, 2018 (33) Prospective, open- 102 57.8 77% - T2DM, proven insulin resistance 
2 
 
label, randomised (±11.0) 
Osonoi et al, 2018 (43) Observational, open-
label  20 
62.9 
(±8.6)  
75% 0% T2DM, moderate albuminuria 
Tan and Tan, 2018 (47) Conference abstract 32 52.2 100% 0% Male, T2DM 





75% 0% T2DM 
Bouchi et al, 2017 (37) Prospective, 
randomised, single-




74% 0% T2DM, BMI ≥25 kg/m2 







T2DM, NASH, One to three of: 
metabolic syndrome, hypertension 
and dyslipidaemia 






66.7% - T2DM 
Solini et al. 2017 (49) Prospective, 
observational 
16 57 .0 
(±9.0) 
69% 0% T2DM, BMI <40 kg/m2 















label, single-arm  
27 49.7 
(±9.0) 
63% - T2DM, BMI >25 kg/m2 




- - - New T2DM 








78% 1.7% Drug-naive T2DM, BMI ≤40 kg/m2 









T2DM, BMI ≤45.0 kg/m2 














Study population characteristics. (-) represents omission of data. Equality of loss-to-follow up refers to equal or unequal drop out 
between intervention arms of the study. T2DM = type 2 diabetes mellitus, NAFLD = non-alcoholic fatty liver disease, HF = heart 




Table 2a: Changes in serum inflammatory biomarkers 
 
Study Comparison  Absolute change from 
baseline 
[±SD] 
(% change)  
Control-subtracted 





Iannantuoni et al, 
2019 (48) 
24 week empagliflozin 10mg vs baseline Decrease  - <0.05 
Bosch et al 2019 
(46) 






Sezai et al 2019 
(40) 






Study Comparison  Absolute change from 
baseline 
[±SD] 
(% change)  
Control-subtracted 
change from baseline 
(% change) 
p value 





Noda et al 2019 
(42) 









Eriksson et al, 2018 
(36) 











Garvey et al, 2018 
(30) 







Osonoi et al 2018 
(43) 




Bouchi et al, 2017 
(37) 






Tobita et al, 2017 
(38) 





Okamoto et al, 2016 
(35) 






Ferrannini et al, 
2010 (52) 
24 week 2.5, 5 or 10mg dapagliflozin, morning or night vs baseline and placebo  
 









Eriksson et al, 2018 12 week dapagliflozin 10mg vs baseline and placebo -298 -166 >0.05 
5 
 
Study Comparison  Absolute change from 
baseline 
[±SD] 
(% change)  
Control-subtracted 
change from baseline 
(% change) 
p value 
(36) (-6.0%) (-3.3%) 
Garvey et al, 2018 
(30) 







Bouchi et al, 2017 
(37) 






Tobita et al, 2017 
(38) 





Matsumura et al, 
2017 (34) 





Okamoto et al, 2016 
(35) 






Bailey et al, 2012 
(51) 
























Serum TNF-α  
(pg/ml) 
Garvey et al, 2018 
(30) 







Tan and Tan, 2018 
(47) 















Study Comparison  Absolute change from 
baseline 
[±SD] 
(% change)  
Control-subtracted 
change from baseline 
(% change) 
p value 
Sato et al, 2018 
(41) 





Matsumura et al, 
2017 (34) 







Heerspink et al, 
2019 (31) 










Dekkers et al 2018 
(32) 
12 week dapagliflozin 10mg vs placebo and baseline  
 
(-24.0%)* 
[-37.9, -7.0] † 
(-23.3%) 0.01 
Garvey et al, 2018 
(30) 







Tan and Tan, 2018 
(47) 














Bouchi et al, 2017 
(37) 








Table 2b: Changes in oxidative stress biomarkers 
Study Comparison  Absolute change from baseline 
[±SD] 
(% change)  






Study Comparison  Absolute change from baseline 
[±SD] 
(% change)  





Eriksson et al, 2018 
(36) 
12 week dapagliflozin 10mg/day vs placebo 







Solini et al, 2017 (49) 2 days after single 10mg dapagliflozin treatment 24-hr  





Zhou et al, 2016 (50) Dapagliflozin (between 5-10mg) vs placebo 
Serum (pg/mL) 
Decrease  - 0.034 
Nishimura et al, 2015 
(45) 
Empagliflozin 10mg vs placebo - 28 day urinary 8-iso-







Empagliflozin 25mg vs placebo- 28 day urinary 8-iso-








Empagliflozin 10mg vs placebo, 28 day urinary 8-iso-







Empagliflozin 25mg vs placebo, 28 day urinary 8-iso-








Shigiyama et al, 2017 
(44) 
16 week dapagliflozin 5mg/day + Metformin 750mg/day 
vs Metformin 1500mg/day 








Matsumura et al, 2017 Day 7 canagliflozin 100 mg/day vs baseline  -0.6 - <0.05 
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Study Comparison  Absolute change from baseline 
[±SD] 
(% change)  









Serum biomarkers of inflammation (Table 1a) and direct biomarkers of oxidative stress (Table 1b). (-) represents information being 
unavailable or not relevant due to study design. SD represents the standard deviation of absolute mean average change in a 
biomarker from baseline, this was estimated where not directly available. % change represents the percentage change of a 
biomarker from baseline. * = median, † = 25th to 75th percentile, $ = least mean square percentage change. CRP = c-reactive 
protein, TNF α = tumour factor alpha necrosis, IL6 = interleukin-6, hsCRP = high-sensitivity c-reactive protein, 2,3-dinor-8-iso-




















Absolute change in CRP compared with absolute change in HbA1c from baseline to follow-up. The Pearson’s correlation coefficient 
(r) is displayed.  
Supplementary tables 
Supplementary table 1a – comprehensive overview of changes in inflammatory biomarkers 
Study Type of Study n 
 






























et al, 2019 
(48) 
Observational, prospective, 
open-label study 17 Empagliflozin 10 mg vs baseline  
Long-standing (>10 years) T2DM 
patients aged between 40-70. 
24 week hsCRP 
(mg/L) - - - Decreased - < 0.05 - - - - 
24 week IL10 
(pg/mL) - - - Decreased - < 0.05 - - - - 
Bosch et al 




25 mg Empagliflozin vs placebo and 
baseline 
 




*excludes patients with CRP >5 mg/L 
6 week hsCRP 
(mg/L) 2.10  (1.72) 1.88  (1.32) 1.99  (1.19)  - 10.5% 0.283 - 5.2% 0. 583 + 5.3% 0.458 
Heerspink et 
al, 2019 (31) Retrospective analysis from a prospective randomised 
double-blind, controlled trial 
(CANTATA-SU trial) 
 
296 Canagliflozin 100 mg and 300 mg vs 
Glimepiride as least mean square 
 
T2DM patients with urinary 
albumin/creatinine ratio >1.7 
 104 week 
TNFR1  
100 mg  






- - - - - - - - - 9.2% < 
0.001 
104 week IL6  
100 mg - - - - - - - - - 26.3% 0.011 
104 week IL6  




- - - - - - - - - 16.3% 0.110 
104 week 
MMP7 300 mg - - - - - - - - - 24.9% 0.011 
104 week 
MMP8 100 mg 
 
- - - - - - - - - 7.4% 0.360 
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Study Type of Study n 
 






























MMP8 300 mg - - - - - - - - - 15.5% 0.070 
104 week 
fibronectin 1  
100 mg 
- - - - - - - - - 15.8 0.040 
104 week 
fibronectin 1  
300 mg 
- - - - - - - - - 14.9 0.055 
Aso et al 
2019 (39) Prospective, randomised, open‐label, blinded endpoint 
trial 
57 Dapagliflozin 5 mg/day vs baseline 
and standard care  
 
T2DM patients with NAFLD 
 
(median + IQR) 
 
24 week ferritin 






(36.3, 116.0) + 21.7% 0.727 - 41.5% <0.001 - 63.2% - 
24 week TGF-
β1 (ng/mL) 1.29  (0.97, 1.81) 1.32  (1.00, 2.29) 1.20  (0.98, 
1.45) 
1.11  
(0.98, 1.51) - 7.0% 0.229 - 15.9% 0.016 - 8.9% - 




(0.44, 2.53) 1.08  (056, 4.11) 1.79  (0.39, 
2.55) 
1.62  
(0.91, 4.67) + 36.6% 0.389 + 50.0% < 0.001 + 13.4 - 
Sezai et al 
2019 (40) Prospective, randomised, open-label, add-on, controlled trial 
(CANOSSA trial) 
35 Canagliflozin 100 mg vs baseline 
 




*SD calculated from SEM 
 
12 month CRP 
(mg/L) - 4.21  (2.07) - 3.47  (1.72) - - - 17.6% > 0.05 - - 
12 month Hs-
CRP (mg/L) - 0.39  (0.41) - 0.21  (0.24) - - - 46.2% < 0.05 - - 
12 month RLP-
cho (mg/dL) - 5.89  (5.56) - 3.69  (3.67) - - - 37.4% < 0.05 - - 
12 month 
EPA/AA ratio - 0.52  (0.41) - 0.57  (0.35) - - + 9.6% > 0.05 - - 
Noda et al 





14 day hs-CRP 
(mg/L) 2.57 (2.72) 2.14 (2.93) 1.85 (2.38) - 16.7% - - 28.2% - - 13.8% > 0.05 
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Study Type of Study n 
 





























Dekkers et al 
2018 (32) Prospective, randomised, double-blind, placebo-
controlled cross-over clinical 
trial 
31 Dapagliflozin 10 mg vs placebo and 
baseline  
 
T2DM patients with alb/cr ratio > 100 
mg/g + < 3500 mg/g 
 
(median pg/24h + 25th to 75th 
percentile) 
12 weeks total 
IgG (pg/24 h) 
 
2269  
(875-4600) - - + 4.3%  (-12.4, 
24.2) 




0.010 - 29.6 - 
12 weeks total 
IgG4 (pg/24 h) 4 (1-8) - - + 3.6%  (-21.0, 
36.0) 
0.800 - 32.2%  
(-49.1, -
9.7) 
0.010 - 35.8 - 
12 weeks IL6 
(pg/24 h) 3 (2-5) - - - 0.7%  (-18.1, 
20.5) 
0.950 - 24.0%  
(-37.9, -
7.0) 
0.010 - 23.3% - 
Eriksson et 
al, 2018 (36) Multicentre, prospective, randomised placebo-controlled 
double-blind double-dummy 




Dapagliflozin 10 mg vs baseline and 
placebo 
 




12 week CRP 





(3798) 4978 (3142) 5459 4680 - 2.4% > 0.05 - 6.0% > 0.05 - 3.6% - 
12 week leptin 





(23.3) 69.2  (±46.9) 51.6 56.8 - 14.8% > 0.05 - 17.9% > 0.05 - 3.1% - 
Hattori, 2018 
(33) Single centre, open-label, randomised, prospective study 102 Empagliflozin 10 mg vs baseline and placebo  
 




12 month CRP 
(mg/L) 1.46  (1.4) 1.33  (1.0) 1.71  (1.64) 0.59  (0.42) + 17.1% > 0.05 - 55.6% < 0.05 - 72.7% 0.007 
12 month  RLP-
C (mg/dL) 6.27  (3.96) 8.13  (5.02) 7.91  (5.57) 3.94  (2.10) + 26.2% > 0.05 - 51.5% < 0.05 - 77.7% 0.029 
Garvey et al, 
2018 (30) Phase 3, randomised, prospective, double-blind, 
active-controlled trial 
100 Canagliflozin 300 mg vs baseline 
and glimepiride 6mg or 8mg 
 
T2DM patients 
(median +IQR ) 
 
*Excludes patients with CRP >10 
mg/L 
52 week CRP 
(μg/mL) 2.9 (1.4, 5.0) 2.9  (1.4, 5.7) 3.0 2.7  + 3.4% - - 6.9% - - 10.3% - 
52 week TNFα 
(pg/ml) 2.2 (1.8, 2.6) 2.2  (1.8, 2.5) 2.1 2.3 - 4.5% - + 4.5% - + 9.1% - 
52 week IL6 










706.7 729.7  +0.5% - + 2.5% - + 1.6% - 
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Study Type of Study n 
 




































3.0 4.1 0% - + 17.1%  - 17.1% - 
52 week leptin 
(ng/ml) 11.0 (5.8, 19.0) 13.0  (7.8, 20.0) 12.0  11.9 + 9.1% - - 8.5% - - 17.6% - 
Osonoi et al 
2018 (43) Observational, single-arm, open label study 20  
100 mg Canagliflozin vs baseline  
 
T2DM patients with microalbuminuria 
 
(mean SD) 
12 week CRP 
(mg/L) - 0.9  (1.3) - 1.1  (±1.6) - - + 22.2% 0.515 - - 
12 week 
TNFR1 (pg/mL) - 1256  (217) - 1220  (186) - - - 2.8% 0.282 - - 
12 week 
TNFR2 (pg/mL) - 2587  (600) - 2826  (605) - - + 9.2% 0.047 - - 
12 week IL-18 
(pg/mL) - 313 (111) - 321  (106) - - + 2.6% 0.705 - - 
Tan and Tan, 
2018 (47) Conference abstract 32 6 months 100 mg canagliflozin then 6 months 10 mg empagliflozin + 6 
months 10 mg empagliflozin then 6 
months 100 mg canagliflozin vs 
baseline 
 
Male T2DM patients  
 
(unspecified dispersion statistics) 
6 month empa 
TNF-α (pg/ml) - 40.1  (6.7) - 25.1  (3.8) - - - 37.4% 0.002 - - 
12 month cana 
then empa 
TNF-α (pg/ml) 
- 40.1  
(6.7) - 26.2  (4.9) - - - 34.7% 0.009 - - 
6 month empa 
IL6 (pg/ml) - 20.2  (8.3) - 9.7  (3.4) - - - 52.0% 0.022 - - 
12 month cana 
then empa IL6 
(pg/ml) 
- 20.2  
(8.3) - 10.6  (4.2) - - - 47.5% 0.011 - - 
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Study Type of Study n 
 





























6 month empa 
IFN-γ (pg/ml) - 23.3  (4.5) - 10.1  (2.4) - - - 56.7% 0.001 - - 
12 month cana 
then empa IFN-
γ (pg/ml) 
- 23.3  
(4.5) - 11.0 (1.4) - - - 52.8% 0.007 - - 
Sato et al, 
2018 (41) Single-centre, randomised, prospective, controlled trial (no 
mention of label blinding) 
40 Dapagliflozin (unspecified dose) vs 
baseline and standard treatment  
 




6 month TNF-α 
(pg/ml) 2.20  (0.7) 2.40  (0.7) 2.23  1.90  1.4% >0.1 - 20.8% <0.05 - 22.2% 0.03 
Bouchi et al, 
2017 (37) Randomised, prospective, single-arm pilot controlled trial 19 Luseogliflozin 2.5 mg vs baseline  
T2DM patients with HbA1c 6.5-9 + 
BMI >25 
 
(mean unspecified dispersion 
statistics) 
*converted from log to original data 
12 month CRP 
(mg/L) - 0.98  (0.35) - 0.79  (0.47) - - - 19.4% 0.392 - - 
12 month IL6 
(pg/ml) - 2.00  (1.70) - 1.34  (1.82) - - - 33% 0.278 - - 
12 month 




- 8.8  
(3.3) - 8.5  (3.4) - - - 3.4% 0.233 - - 
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Study Type of Study n 
 





























Tobita et al, 
2017 (38) Prospective, observational, open-label, uncontrolled pilot 
study 
11 Dapagliflozin 5 mg vs baseline 
 
T2DM patients with NASH 
 
(median + IQR) 
24 week hs-





8.85) - 7.00 (5.60-11.80) - - + 22.9% <0.01 - - 
Matsumura et 
al, 2017 (34) Prospective, observational, open-label study 15 Canagliflozin 100 mg vs baseline  
T2DM patients with metabolic 
syndrome, hypertension and/or 
dyslipidaemia 
 
(median + graphical IQR) 
7 day TNF-α 




- 5.01 - 5.53 - - + 9.4% <0.05 - - 
Okamoto et 
al, 2016 (35) Prospective, observational, single-arm, open-label study 27 Dapagliflozin 5 mg vs baseline  






- 2.41  




- 5.1  
(2.3) - 6.7  (4.2) - - + 33.3% <0.01 - - 
Bailey et al, 
2012 (51) Phase 3, randomised, double-blind, quadruple-arm, placebo-
controlled study 
282  Dapagliflozin 1, 2.5 and 5 mg vs 
baseline and placebo 
 
Antidiabetic naïve T2DM patients 
 
(mean SD) 
24 week Leptin 
(μg/L) 1 mg 26.8  (24.5) 25.06  (23.6) 25.3  (24.3) 23.0  (18.9) - 4.5% - - 8.7% - - 4.2% - 
24 week Leptin 
(μg/L) 2.5 mg 26.8  (24.5) 22.24  (19.15) 25.3  (24.3) 21.0  (19.8) - 4.5% - - 8.9% - - 4.4% - 
24 week Leptin 
(μg/L) 5 mg 26.8  (24.5) 27.9  (31.2) 25.3  (24.3) 22.9  (24.7) - 4.5% - - 15.9% - - 11.4% - 
24 week 
Adiponectin 
(μg/ml) 1 mg 
6.61  
(3.38) 6.39  (2.95) 7.05  (3.35) 7.11  (3.19) + 7.2% - + 11.3% - + 4.1 - 
24 week 
Adiponectin 
(μg/ml) 2.5 mg 
6.61  
(3.38) 6.44  (2.95) 7.05  (3.35) 7.18  (3.51) + 7.2% - + 11.6% - + 4.4% - 
24 week 
Adiponectin 
(μg/ml) 5 mg 
6.61  
(3.38) 6.08  (2.71) 7.05  (3.35) 7.01  (3.25) + 7.2% - + 14.6% - + 7.4% - 
Ferrannini et 
al, 2010 (52) Phase 3, randomised, prospective, parallel-group, 
double-blind, placebo-
controlled trial 
274 2.5, 5 or 10 mg dapagliflozin, 
morning or night vs baseline and 
placebo  
 
Antidiabetic naïve T2DM patients  
 
(placebo-subtracted adjusted mean 
±SEM) 







- -1.53 [±17.5] 
to -2.67 
[±18.2] 
- - - - - 74.5% - 
 




Study Type of Study n Comparison and 
Study Population 

























Sezai et al, 
2019 (40) Prospective, randomised trial (CANOSSA trial) 35 Canagliflozin 100 mg/day  
Chronic T2DM patients 
with heart failure  
 
 
3 month serum Ox-LDL 
(U/L) - - - - - - Decrease < 0.05 - - 
6 month serum Ox-LDL 
(U/L) - - - - - - Decrease < 0.05 - - 
12 month serum Ox-LDL 
(U/L) - - - - - - Decrease < 0.05 - - 
Iannantuoni et 
al, 2019 (48) Observational, prospective, open-label study 17 Empagliflozin 10 mg/day  
Long-standing (>10 
years) T2DM patients 
aged between 40-70. 
12 week leukocyte 
mitochondrial superoxide 
production 
- - - - - - Decrease ≥ 0.05 - - 
24 week leukocyte 
mitochondrial superoxide 
production 
- - - - - - Decrease < 0.05 - - 
12 week leukocyte 
mitochondrial glutathione 
content 
- - - - - - Increase < 0.05 - - 
24 week leukocyte 
mitochondrial glutathione 
content 
- - - - - - Increase < 0.05 - - 
12 week leukocyte 
mitochondrial glutathione s-
reductase mRNA level 
- - - - - - - - - - 
24 week leukocyte 
mitochondrial glutathione s-
reductase mRNA level 
- - - - - - Increase < 0.05 - - 
12 week leukocyte 
mitochondrial catalase 
mRNA level 
- - - - - - - - - - 
24 week leukocyte 
mitochondrial catalase 
mRNA level 
- - - - - - Increase < 0.05 - - 
Eriksson et al, 
2018 (36) Randomised, placebo-controlled, double-blind study 42 Dapagliflozin 10 mg/day vs placebo 12 week serum acetylcarnitine (μmol/l) 10.36  (±3.64) 9.14  (±2.50) - - - 3.3% (±20.5%) ≥ 0.05 + 12.7% (±23.5%) ≥ 0.05 + 16.0% ≥ 0.05 
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Study Type of Study n Comparison and 
Study Population 

























(EFFECT-II study)  
Stable patients with 




12 week serum 2-
hydroxynonenal (pg/ml) 
5.74  
(±1.14) 5.51  (±1.57) - - - 3.0% (±12.0%) ≥ 0.05 - 1.5% (±15.2%) ≥ 0.05 + 1.5% ≥ 0.05 
12 week serum 2-
hydroxyhexanal (pg/ml) 3.76  (±1.35) 3.30  (±0.69) - - - 0.8%  (±30.6%) ≥ 0.05 + 3.3%  (±17.6%) ≥ 0.05 + 4.1% ≥ 0.05 




(±0.068) 0.073  (±0.024) - - - 9.1%  (±37.5%) ≥ 0.05 + 1.4%  (±30.1%) ≥ 0.05 +10.6% ≥ 0.05 




(±0.79) 1.43  (±0.70) - - + 7.0%  (±27.2%) ≥ 0.05 + 25.9%  (±45.5%) ≥ 0.05 + 18.9 ≥ 0.05 
Solini et al, 
2017 (49) Prospective observational trial 16 Dapagliflozin 10 mg  
Outpatients with T2DM 




2 days after single 
dapagliflozin treatment 24-hr 
urinary 8-iso-PGF2α  
(pg/ml)  
- 
         
 
1659  
(±1029) -  
1157  
(±663) - - - 30.3% 0.04 - - 
Shigiyama et 
al, 2017 (44) Prospective, randomised, open-label, blinded-endpoint, 
parallel-group, comparative 
clinical trial (DEFENCE study) 
80 Dapagliflozin 5mg/day + 
Metformin 750 mg/day 
vs5. Metformin 1500 
mg/day 
 
T2DM patients treated 












         
         
5.8  
(±2.3)  
                 
4.0  
(±1.9)  
     
 
+ 22.9%  
(±45.8%) - - 13.0%  (±39.1%) >0.05 - 36.2%  
< 0.001 
Matsumura et 
al, 2017 (34) Prospective observational trial 15 Canagliflozin 100 mg/day from Day 4 onwards. 
 
T2DM patients who had 
received insulin therapy 
for 1 year or more 
Day 7 urinary 8-OHdG 
(ng/mg Cre) - 11.4 - 10.8 - - -5.3% < 0.05 - - 
18 
 
Study Type of Study n Comparison and 
Study Population 

























Zhou et al, 
2016 (50) Randomised, double-blinded, placebo-controlled, parallel 
grouped study 
28 Dapagliflozin vs Placebo 
(dose unclear, between 
5-10mg) 
 
Newly diagnosed T2DM  
24 week serum 8-iso-PGF2α 
(pg/mL) - - - - - - Decrease 0.034 - - 
Nishimura et 
al, 2015 (45) Randomised, double-blind, placebo-controlled, parallel-
group study 
60 Empaglifllozin 10 mg vs 
Empagliflozin 25 mg vs 
Placebo 
 
Stable T2DM patients 
aged 40-74 years with a 
BMI <40. 
 
(adjusted mean ±SE or 
95% CI) 
Empa 10 mg - 28 day 
urinary 8-iso-PGF2α in 
fasting state (pg/mL) 
197.8  
(±27.0) 194.6  (±29.4) - -  + 20.5% (±11.4%) - - 24.7%  (±12.0%) - - 45.2%  (- 78.2%, 
- 11.5%) 
0.010 
Empa 25 mg - 28 day 
urinary 8-iso-PGF2α in 
fasting stage (pg/mL) 
197.8  
(±27.0) 146.5  (±18.5) - - + 20.5%  (±11.4%) - - 22.9%  (±16.2%) - - 43.0%  (- 70.7%, 
- 4.1%) 
0.028 
Empa 10 mg - 28 day 
urinary 8-iso-PGF2α 24 
hours after drug 
administration (pg/mL) 
115.5  
(±11.0) 138.3  (±20.6) - - - 3.2%  (±8.9%) - - 20.5%  (±7.5%) - - 19.5%  (- 47.2%, 
+ 4.5%) 
0.103 
Empa 25 mg - 28 day 
urinary 8-iso-PGF2α 24 
hours after drug 
administration (pg/mL) 
115.5  





Serum biomarkers of inflammation (Table 1a) and direct biomarkers of oxidative stress (Table 1b). (-) represents information being 
unavailable or not relevant due to study design. CRP = c-reactive protein, TNF α = tumour necrosis, IL6 = interleukin-6, IL10 = 
interleukin-10, IL18 = interleukin-18, factor alpha, hsCRP = high-sensitivity c-reactive protein,TNFR1 and 2 = tumor necrosis factor 
receptor 1 and 2, MMP7 and 8 = matrix metalloprotease 7 and 8, TGF-β1 = transforming growth factor beta 1, HMW adiponectin = 
19 
 
high-molecular weight adiponectin, RLP-cho = remnant lipoprotein cholesterol, EPA/AA = eicosapentaenoic acid to arachidonic 
acid ratio, IgG = immunoglobulin G, VCAM-1 = vascular adhesion molecule 1, IFN-γ = interferon gamma, Ox-LDL = oxidised low-
density lipoprotein, mRNA = messenger ribonucleic acid, 8-iso-PGF2α = 8-iso-prostaglandin F2α, 2,3-dinor-8-iso-PGF2α = 2,3-
dinor-8-iso-prostaglandin F2α, 8-OHdG = 8-hydroxy-2' –deoxyguanosine, SD = standard deviation, 95% CI = 95% confidence 
interval, SEM = standard error of the mean, IQR = interquartile range, T2DM = type 2 diabetes mellitus, CRP = c-reactive protein, 

















Study design Risk of 
bias 
Inconsistency Indirectness Imprecision Other considerations 
Follow-up serum C-Reactive Protein (CRP) 
12 7 randomised 
trials 
 
serious a not serious not serious serious b all plausible residual 
confounding would 
suggest spurious 







serious c not serious not serious serious b all plausible residual 
confounding would 
suggest spurious 





Follow-up serum Adiponectin 
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Study design Risk of 
bias 
Inconsistency Indirectness Imprecision Other considerations 
8 5 randomised 
trials 
  
serious d not serious not serious serious b all plausible residual 
confounding would 
suggest spurious 








serious e not serious not serious serious b all plausible residual 
confounding would 
suggest spurious 





Follow-up serum Interleukin-6 (IL6) 
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Study design Risk of 
bias 






serious f not serious not serious serious b all plausible residual 
confounding would 
suggest spurious 







serious g not serious not serious serious b all plausible residual 
confounding would 
suggest spurious 





Tumour Necrosis Factor alpha (TNF-α) 
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Study design Risk of 
bias 
Inconsistency Indirectness Imprecision Other considerations 
4 2 randomised 
trials 
 
serious h not serious not serious serious b all plausible residual 
confounding would 
suggest spurious 







serious i not serious not serious serious b all plausible residual 
confounding would 
suggest spurious 





8-iso-prostaglandin F2α (8-iso-PGF2α) 
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Study design Risk of 
bias 








not serious not serious serious b all plausible residual 
confounding would 
suggest spurious 









not serious not serious serious b all plausible residual 
confounding would 
suggest spurious 









a) 1) Selection bias as Bosch et al 2019 recruited from local newspapers 2) performance and detection bias due to non-blinding 
in Aso et al 2019, Sezai et al 2019, Hattori 2018 and Bouchi et al 2017 3) attrition bias due to loss to follow up bias due to 
Heerspink et al 2019, Eriksson et al 2018, and potential loss to follow up due to Bosch et al 2019, Hattori 2018 and Okamoto 
et al 2016. 
b) Wide standard deviations across results 
c) 1) Selection bias due to non-randomisation of Noda et al 2019, Osonoi et al 2018, Tobita et al 2017 and Okamoto et al 2016  
2) performance and detection bias due to non-blinding in Noda et al 2019, Osonoi et al 2018, Tobita et al 2017 and Okamoto 
et al 2016 3) attrition bias due to loss to follow up bias due to Noda et al 2019, Tobita et al 2017, and potential loss to follow 
up due to Okamoto et al 2016. 
d) 1) Performance and detection bias due to non-blinding in Aso et al 2019, Bouchi et al 2017 2) attrition bias due to loss to 
follow up bias due to Eriksson et al 2018 and Bailey et al 2012.  
e) 1) Selection bias due to non-randomisation of Tobita et al 2017, Matsumura et al 2017 and Okamoto et al 2016 2) 
performance and detection bias due to non-blinding in Tobita et al 2017, Matsumura et al 2017 and Okamoto et al 2016 3) 




f) 1) Performance and detection bias due to non-blinding in Bouchi et al 2017 2) attrition bias due to loss to follow up bias due 
to Heerspink et al 2019 
g) 1) Selection bias due to non-randomisation of Osonoi et al 2018 and potential selection bias due to no mention of 
randomisation in Tan and Tan 2018 2) performance and detection bias due to non-blinding in Osonoi et al 2018, Bouchi et al 
2017 and potentially Tan and Tan 2018. 
h) 1) Potential bias due to no mention of blinding in Sato et al 2018 2) attrition bias due to loss to follow up bias due to Garvey 
et al 2018 and potentially Tan and Tan 2018 and Matsumura et al 2017. 
i) 1) Potential selection bias due to no mention of randomisation in Tan and Tan 2018 2) performance and detection bias due 
to non-blinding in Matsumura et al 2017 3) attrition bias due to loss to follow up bias potentially due to Tan and Tan 2018 
and Matsumura et al 2017. 
j) 1) Potential attrition bias due to no mention of loss to follow up in Zhou et al 2016. 






Supplementary table 3a - Cochrane Risk-of-Bias Tool for Randomised trials (RoB 2) 
 
First Author, 
Year (Ref. #) 
Bias due to 
randomisation 
process 
Bias in assignment and 
adherence to 
intervention 
Bias due to Loss 
to follow up 
Bias due to 
measurement of 
outcomes 
Bias in selection 
of reported 
result 
Overall risk of 
bias judgment 
Follow-up serum C-Reactive Protein (CRP) 
Bosch, 2019 Low Low Unavailable Low Low Some 
concerns 
Sezai, 2019 Low High Low Some concerns Low High 
Eriksson, 2018 Low Low Low Low Low Low 
Hattori, 2018 Low High Unavailable Some concerns Low Some 
concerns 
Garvey, 2018 Low Low Some concerns Low Low Some 
concerns 




Low Low Low Low Low Low 
Follow-up serum Adiponectin 




Year (Ref. #) 
Bias due to 
randomisation 
process 
Bias in assignment and 
adherence to 
intervention 
Bias due to Loss 
to follow up 
Bias due to 
measurement of 
outcomes 
Bias in selection 
of reported 
result 
Overall risk of 
bias judgment 
Eriksson, 2018 Low Low Low Low Low Low 
Garvey, 2018 Low Low Some concerns Low Low Some 
concerns 
Bouchi, 2017 Low Some concerns Low Some concerns Low Some 
concerns 
Bailey 2012 Low Low High Low Low High 
Follow-up serum Interleukin-6 (IL6) 
Heerspink, 
2019 
Low Low Some concerns Low Low Some 
concerns 
Dekkers, 2018 Low Low Low Low Low Low 
Bouchi, 2017 Low Some concerns Low Some concerns Low Some 
concerns 
Follow-up serum Tumour Necrosis Factor alpha (TNF-α) 
Garvey 2018 Low Low Some concerns Low Low Some 
concerns 
Sato 2018 Low Some concerns Low Low Low Some 
concerns 




Year (Ref. #) 
Bias due to 
randomisation 
process 
Bias in assignment and 
adherence to 
intervention 
Bias due to Loss 
to follow up 
Bias due to 
measurement of 
outcomes 
Bias in selection 
of reported 
result 
Overall risk of 
bias judgment 
Sezai, 2019 Low Some concerns Low Some concerns Low High 
Eriksson, 2018 Low Low Low Low Low Low 
Shigiyama, 
2017 
Low Low Low Low Low Low 




Low Low Low Low Low Low 
 
Supplementary table 3b - Cochrane Risk-of-Bias Tool for Non-Randomised trials (ROBINS-I) 
 
First author, Year 
(Ref. #) 














Bias due to 
missing data 










Follow-up serum C-Reactive Protein (CRP) 
Iannantuoni, 2019 Low  Low  Low  Low  Serious  Moderate  Low  Serious  
Noda, 2019 Low  Low  Low  Low  Serious  Low   Low  Serious  
Osonoi, 2018 Moderate  Low  Low  Low  Low  Moderate  Low  Moderate  
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Tobita, 2017 Low  Low  Low  Low  Moderate  Moderate  Low  Moderate  
Okamoto, 2016 Low  Low  Low  Low  Unavailable  Moderate  Low  Moderate  
Follow-up serum Adiponectin 
Tobita, 2017 Low  Low  Low  Low  Moderate  Moderate Low  Moderate  
Matsumura, 2017 Moderate  Low  Low  Low  Unavailable Moderate Low  Moderate  
Okamoto, 2016 Low  Low  Low  Low  Unavailable Moderate Low  Moderate 
Follow-up serum Interleukin-6 (IL6) 
Tan and Tan, 2018 Unavailable  Moderate  Low  Low  Low  Moderate Low  Moderate 
Follow-up serum Tumour Necrosis Factor alpha (TNF-α) 
Tan and Tan, 2018 Unavailable  Moderate  Low  Low  Low  Moderate Low  Moderate 
Matsumura, 2017 Moderate  Low  Low  Low  Unavailable Moderate Low  Moderate 
Oxidative stress biomarkers 
Iannantuoni, 2019 Low  Low  Low  Low  Serious  Moderate Low  Serious   
Solini, 2017 Low  Low  Low  Low  Low  Moderate Low  Moderate  
















Study Participant co-morbidity from inclusion criteria Co-morbidity 
score 
Pharmacological intensity 
from inclusion criteria 
Pharmacological 
intensity score 
Bosch et al  Nil  0 4 months antidiabetic medication 
free. 
0 
Sezai et al Nil  0 Any concomitant oral antidiabetic 
medication 
2 
Noda et al Nil  0 metformin only or no antidiabetic 
medications. 
1 
Eriksson et al NAFLD + overweight 9 metformin or a sulfonylurea for 3 
months 
1 
Hattori Overweight  1 Any antidiabetic medications 2 
Garvey et al Nil  0 metformin for at least 10 weeks 1 
Osonoi et al Moderate albuminuria: albumin-to-creatinine ratio of 
30.0–299.9 mg/g creatinine 
4 Any antidiabetic medications 2 
Bouchi et al Overweight  1 Any antidiabetic medication insulin 2 
Tobita et al NASH 
One to three of: metabolic syndrome, hypertension and 
dyslipidaemia 
9 Any antidiabetic except insulin 2 
Okamoto et al Overweight  1 Any antidiabetic medication 2 
Ferrannini et al Overweight  1 None  0 
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Supplementary table 5a – SGLT2i AND Inflammation biomarker Search Strategy 
Medline - Inflammation 
1 exp Sodium-Glucose Transporter 2 Inhibitors/ 1941 
2 gliflozin*.mp. 78 
3 (sglt$2 inhibitor* or sglt2 inhibitor* or sodium glucose cotransporter 2 inhibitor*).mp. 1784 
4 1 or 2 or 3 2544 
5 exp Oxidative Stress/ 127771 
6 oxidative stress.mp. 185263 
7 exp Biomarkers/ 716403 
8 biomarker*.mp. 486108 
9 5 or 6 or 7 or 8 962286 
10 4 and 9 236 
Embase - Inflammation 
1 exp Sodium-Glucose Transporter 2 Inhibitors/ 9226 



















3 (sglt$2 inhibitor* or sglt2 inhibitor* or sodium glucose cotransporter 2 inhibitor*).mp. [mp=title, 
abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, 
device trade name, keyword, floating subheading word, candidate term word] 
6452 
4 1 or 2 or 3  9800 
5 exp Oxidative Stress/ 276341 
6 oxidative stress.mp. 322267 
7 exp Biomarkers/ 288044 
8 biomarker*.mp. 391559 
9 5 or 6 or 7 or 8 777768 
10 4 and 9 502 
Web of Science - Inflammation 
#1 TS=((gliflozin* or sglt$2 inhibitor* or sglt2 inhibitor* or sodium glucose cotransporter 2 inhibitor*) 
and (oxidative stress or biomarker*)) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years 
208 
Cochrane Library - Inflammation 
1 Trials matching ((gliflozin* or sglt$2 inhibitor* or sglt2 inhibitor* or sodium glucose cotransporter 2 





Supplementary table 5b – SGLT2i AND Oxidative stress biomarker Search Strategy 
Medline – Oxidative stress 
1 exp Sodium-Glucose Transporter 2 Inhibitors/ 1981 
2 gliflozin*.mp. 90 
3 (sglt$2 inhibitor* or sglt2 inhibitor* or sodium glucose cotransporter 2 inhibitor*).mp. 2743 
4 1 or 2 or 3 3532 
5 exp Inflammation/ 323188 
6 inflammat*.mp. 996341 
7 exp Biomarkers/ 719201 
8 biomarker*.mp. 543320 
9 5 or 6 or 8 or 9 1789936 
10 4 and 9 375 
Embase - Oxidative stress 












2 gliflozin*.mp. 184 
3 (sglt$2 inhibitor* or sglt2 inhibitor* or sodium glucose cotransporter 2 inhibitor*).mp. 6527 
4 1 or 2 or 3 9898 
5 exp Inflammation/ 3172840 
6 inflammat*.mp. 1451823 
7 exp Biomarkers/ 289495 
8 biomarker*.mp. 393435 
9 5 or 6 or 8 or 9 4504940 
10 4 and 9 1677 
Web of Science – Oxidative Stress 
#1 TS=((gliflozin* or sglt$2 inhibitor* or sglt2 inhibitor* or sodium glucose cotransporter 2 inhibitor*) 
and (inflamma* or biomarker*)) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years 
249 
Cochrane Library - Oxidative Stress 
1 Trials matching ((gliflozin* or sglt$2 inhibitor* or sglt2 inhibitor* or sodium glucose cotransporter 2 
inhibitor*) and (inflamm* or biomarker*)) in Title Abstract Keyword 
123 
